Mechanism of Action (MoA)

The precise biomolecular entity—typically a protein receptor, enzyme, ion channel, or nucleic acid—to which a drug binds to initiate its effect. Specificity is governed by structural complementarity and binding affinity.

• Receptor Agonism: Drug mimics endogenous ligand to activate signaling (e.g., morphine at μ-opioid receptor)
• Receptor Antagonism: Drug blocks endogenous ligand binding without activating (e.g., naloxone)
• Enzyme Inhibition: Competitive, non-competitive, or irreversible blockade of catalytic activity (e.g., statins inhibiting HMG-CoA reductase)
• Ion Channel Modulation: Opening or blocking voltage-gated or ligand-gated channels (e.g., lidocaine blocking sodium channels)

The quantitative relationship between drug concentration and target occupancy over time. Binding affinity (Kd) measures the equilibrium dissociation constant, while residence time captures how long the drug remains bound.

• Kd: Lower values indicate tighter binding; typical drugs range from nanomolar to micromolar
• Kon/Koff rates: Association and dissociation rate constants determine onset and duration of action
• Residence time: Longer target engagement often correlates with extended pharmacodynamic effects beyond plasma clearance
• IC50/EC50: Functional measures of half-maximal inhibitory or effective concentration in cellular assays

The intracellular biochemical pathways activated or suppressed following target engagement. These signal transduction networks amplify the initial binding event into a cellular response.

• G-protein coupled receptors (GPCRs): Activate second messengers like cAMP, IP3, and calcium
• Kinase cascades: Phosphorylation relays such as MAPK/ERK or PI3K/AKT/mTOR
• Transcription factor activation: Nuclear translocation and gene expression modulation (e.g., steroid hormone receptors)
• Allosteric modulation: Binding at a site distinct from the orthosteric pocket to fine-tune receptor activity rather than fully activating or blocking

The observable cellular or physiological outcome resulting from the molecular MoA. This connects the biochemical mechanism to the therapeutic effect and distinguishes on-target efficacy from off-target toxicity.

• Apoptosis induction: Programmed cell death triggered by DNA damage or survival signal inhibition
• Cell cycle arrest: Halting proliferation at specific checkpoints (G1/S, G2/M)
• Immune modulation: Checkpoint blockade or cytokine release altering immune surveillance
• Metabolic reprogramming: Shifting energy utilization pathways in cancer or metabolic disease

The systematic analysis of how chemical modifications to a drug's molecular scaffold alter its MoA and potency. SAR studies are foundational to medicinal chemistry optimization.

• Pharmacophore mapping: Identifying the essential 3D arrangement of functional groups required for target binding
• Bioisosteric replacement: Swapping chemical groups to improve properties while retaining MoA
• Stereochemistry effects: Enantiomers can exhibit dramatically different target engagement (e.g., (S)-citalopram vs. (R)-citalopram)
• Scaffold hopping: Replacing the core molecular framework to generate novel intellectual property while preserving the pharmacophore

The phenomenon where a drug engages multiple molecular targets beyond its primary intended receptor. This can produce therapeutic synergy or adverse side effects depending on the secondary targets involved.

• Kinase promiscuity: ATP-competitive inhibitors often hit multiple kinases due to conserved binding pockets
• GPCR cross-reactivity: Structural similarity among receptor subtypes leads to unintended activation
• hERG channel blockade: Off-target cardiac ion channel interaction causing QT prolongation—a major safety liability
• Computational profiling: Machine learning models predict off-target binding across the proteome to anticipate polypharmacology early in development

The physical binding event between a chemical compound and a specific biomolecule, typically a protein, which modulates a biological process. Binding affinity (Kd, IC50) quantifies the strength of this interaction.

• Key Concept: The molecular initiating event of an MoA.
• AI Application: Graph neural networks predict binding poses and affinities to screen for novel targets.
• Example: Imatinib binds to the BCR-ABL kinase domain, inhibiting ATP binding.

The experimental or computational process of identifying the specific molecular target through which a biologically active compound exerts its phenotypic effect. This is the reverse engineering of an MoA.

• Methods: Affinity-based proteomics, CRISPR screens, and knowledge graph embeddings.
• Challenge: Many drugs exhibit polypharmacology, binding multiple targets.
• AI Role: Causal inference models distinguish primary targets from downstream effectors.

The design or functional capacity of a single drug molecule to interact with multiple distinct biological targets simultaneously, producing a complex therapeutic or adverse effect profile.

• Therapeutic Polypharmacology: Intentional multi-target engagement for complex diseases like cancer.
• Adverse Polypharmacology: Off-target binding leading to side effects.
• Modeling: Multi-task neural networks predict activity across an entire panel of targets.

The computational forecasting of adverse drug reactions by modeling the interaction between a drug's chemical structure and off-target biological pathways.

• Input Data: Chemical fingerprints, protein target profiles, and transcriptomic signatures.
• Technique: Matrix factorization of drug-side effect association networks.
• Value: Early identification of safety liabilities reduces late-stage clinical trial failure.

A computational approach that compares a disease's gene expression pattern against a reference database of drug-induced gene expression changes to identify compounds that reverse the disease state.

• Core Resource: The Connectivity Map (CMap).
• Mechanism: If a drug's signature is the inverse of a disease signature, it suggests a therapeutic MoA.
• Output: A ranked list of candidate repurposing drugs with a connectivity score.

A machine learning technique that projects the entities and relations of a biomedical knowledge graph into a low-dimensional vector space to predict missing links, such as novel drug-disease associations.

• Graph Components: Nodes (drugs, targets, diseases, pathways) and Edges (binds, treats, causes).
• Algorithms: TransE, RotatE, and graph convolutional networks.
• MoA Insight: Predicted links can reveal the mechanistic pathway connecting a drug to a phenotype.